Association of MTHFR C677T and A1298C Gene Polymorphisms with Methotrexate Efficiency and Toxicity in Algerian Rheumatoid Arthritis Patients

Overview

Journal Heliyon

Specialty Social Sciences

Date 2017 Dec 22

PMID 29264421

Citations 6

Authors

Lilya M Berkani

Fadia Rahal

Ines Allam

Soraya Mouaki Benani

Aicha Laadjouz

Reda Djidjik

Affiliations

Soon will be listed here.

Abstract

Methotrexate (MTX) is the most used drug in rheumatoid arthritis (RA) treatment. However, it shows variability in clinical response, which is explained by an association with genetic polymorphisms. This study aimed to elucidate the role of the two gene polymorphism C677T and A1298C of the methylenetetrahydrofolate reductase (MTHFR) in response to MTX in Algerian RA patients. Study included 54 early RA patient treated with MTX for one year. MTX efficiency and toxicity were evaluated at 6 and 12 months respectively and the two gene polymorphisms were genotyped. No association was found between A1298C polymorphism and MTX toxicity. However, T allele of the C677T polymorphism was associated with the occurrence of MTX adverse effects (p = 0,019, OR: 3,63, 95% CI [1,12 - 12,80]). No association was found between C677T polymorphism and MTX efficiency, while A allele of the A1298C polymorphism was associated with good and moderate response (p = 0,02, OR = 3,28, 95% CI: [1,11- 9,42]). The study of RA biological markers kinetics showed that MTX did not affect antibodies rate unlike inflammatory markers. Our study suggests that MTHFR C677T and A1298C genotyping are associated to MTX toxicity and efficiency, respectively, in RA patients. This offers new perspectives in the personalization of RA treatment in Algeria.

Citing Articles

AMPD1 and MTHFR genes are not associated with calcium levels in rheumatoid arthritis patients with methotrexate therapy in Indonesia.

Destiani D, Dewi S, Sulaiman S, Alfian S, Barliana M, Abdulah R Sci Rep. 2025; 15(1):1647.

PMID: 39794365 PMC: 11723994. DOI: 10.1038/s41598-024-69604-z.

Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients.

Mutlak Q, Kasim A Sci Rep. 2024; 14(1):15119.

PMID: 38956106 PMC: 11219777. DOI: 10.1038/s41598-024-65199-7.

MTHFR and MTRR Genetic Polymorphism of Methotrexate Therapy Outcomes in Early Rheumatoid Arthritis.

Zhang Q, Fu P, Cao Z, Huang H, Wen Q, Wang K Pharmgenomics Pers Med. 2023; 16:407-423.

PMID: 37159804 PMC: 10163902. DOI: 10.2147/PGPM.S404949.

A Review of Clinical Applications and Side Effects of Methotrexate in Ophthalmology.

Wang G, Peng X J Ophthalmol. 2020; 2020:1537689.

PMID: 32850138 PMC: 7439192. DOI: 10.1155/2020/1537689.

Association of and gene polymorphisms with methotrexate efficacy and toxicity in Chinese Han patients with rheumatoid arthritis.

Wang S, Zuo S, Liu Z, Ji X, Yao Z, Wang X J Int Med Res. 2019; 48(2):300060519879588.

PMID: 31617429 PMC: 7607194. DOI: 10.1177/0300060519879588.

References

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9):1580-8. DOI: 10.1136/ard.2010.138461. View

Caliz R, Del Amo J, Balsa A, Blanco F, Silva L, Sanmarti R . The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. Scand J Rheumatol. 2011; 41(1):10-4. DOI: 10.3109/03009742.2011.617312. View

Mikuls T, ODell J, Stoner J, Parrish L, Arend W, Norris J . Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004; 50(12):3776-82. DOI: 10.1002/art.20659. View

Chen H, Lin K, Chen C, Liao H, Wang H, Chang H . The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2005; 65(1):35-9. PMC: 1797988. DOI: 10.1136/ard.2005.038851. View

Mena J, Salazar-Paramo M, Gonzalez-Lopez L, Gamez-Nava J, Sandoval-Ramirez L, Sanchez J . Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. Pharmacogenomics J. 2010; 11(4):287-91. DOI: 10.1038/tpj.2010.32. View

Zeng Q, Wang Y, Xiao Z, Chen S . Pharmacogenetic study of 5,10-methylenetetrahydrofolate reductase C677T and thymidylate synthase 3R/2R gene polymorphisms and methotrexate-related toxicity in Chinese Han patients with inflammatory arthritis. Ann Rheum Dis. 2008; 67(8):1193-4. DOI: 10.1136/ard.2007.085266. View

van der Put N, Gabreels F, STEVENS E, Smeitink J, Trijbels F, Eskes T . A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998; 62(5):1044-51. PMC: 1377082. DOI: 10.1086/301825. View

Modi S, Soejima M, Levesque M . The effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responses. Clin Exp Immunol. 2013; 173(1):8-17. PMC: 3694530. DOI: 10.1111/cei.12114. View

Song G, Bae S, Lee Y . Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2014; 33(12):1715-24. DOI: 10.1007/s10067-014-2645-8. View

10.

Hoekstra M, van Ede A, Haagsma C, Van de Laar M, Huizinga T, Kruijsen M . Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis. 2003; 62(5):423-6. PMC: 1754533. DOI: 10.1136/ard.62.5.423. View

11.

Hider S, Silman A, Thomson W, Lunt M, Bunn D, Symmons D . Can clinical factors at presentation be used to predict outcome of treatment with methotrexate in patients with early inflammatory polyarthritis?. Ann Rheum Dis. 2008; 68(1):57-62. PMC: 2596302. DOI: 10.1136/ard.2008.088237. View

12.

Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A . Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis. 2004; 63(10):1218-21. PMC: 1754775. DOI: 10.1136/ard.2003.014647. View

13.

Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E . Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics. 2007; 17(6):383-90. DOI: 10.1097/01.fpc.0000236326.80809.b1. View

14.

Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen S, Hetland M . QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. Ann Rheum Dis. 2007; 66(11):1491-6. PMC: 2111618. DOI: 10.1136/ard.2006.069252. View

15.

Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y . Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002; 12(3):183-90. DOI: 10.1097/00008571-200204000-00002. View

16.

Hashiguchi M, Tsuru T, Miyawaki K, Suzaki M, Hakamata J, Shimizu M . Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis. J Pharm Health Care Sci. 2016; 2:13. PMC: 4895805. DOI: 10.1186/s40780-016-0047-6. View

17.

Davis L, Polk B, Mann A, Wolff R, Kerr G, Reimold A . Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2014; 32(3):324-32. PMC: 4167828. View

18.

Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T . Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis. 2004; 63(10):1227-31. PMC: 1754756. DOI: 10.1136/ard.2003.016337. View

19.

Wessels J, de Vries-Bouwstra J, Heijmans B, Slagboom P, Goekoop-Ruiterman Y, Allaart C . Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum. 2006; 54(4):1087-95. DOI: 10.1002/art.21726. View

20.

Frosst P, Blom H, Milos R, Goyette P, Sheppard C, Matthews R . A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10(1):111-3. DOI: 10.1038/ng0595-111. View